Leucine-rich repeat-containing 8A (LRRC8A) is a ubiquitously expressed transmembrane protein that functions as the essential component of volume-regulated anion channels (VRACs). These channels are integral to maintaining osmotic balance, metabolite transport, and intercellular communication, thereby ensuring ion homeostasis and facilitating cellular responses to hypotonic stress, oxidative damage, and mechanical cues.

In addition to its canonical functions, accumulating evidence has implicated LRRC8A in the pathogenesis of various diseases. Consequently, understanding its regulatory roles may open new avenues for developing targeted therapeutics and treatment strategies directed at VRAC channels. A recent Genes & Diseases review by researchers from Tongji Medical College of Huazhong University of Science and Technology outlines how LRRC8A extends its primary role in osmotic regulation to serve as a sophisticated signaling scaffold across oncology, neurology, metabolism, and immunology.

Structurally, LRRC8A forms heteromeric complexes with other LRRC8 family members (LRRC8B–E) to constitute functional VRACs, with subunit composition influencing channel permeability and substrate specificity. These channels mediate the transport of chloride as well as the efflux of organic molecules such as taurine, glutamate, ATP, and certain chemotherapeutic agents. This highlights that LRRC8A activity extends beyond osmotic adaptation to modulating intracellular signaling pathways, redox balance, and metabolite exchange.

LRRC8A exhibits context-dependent duality in oncology, promoting key hallmarks of cancer such as cell proliferation, epithelial-mesenchymal transition (EMT), and metastasis. Its upregulation in esophageal, gastric, colorectal, and pancreatic cancers drives proliferation and invasion via the PI3K/AKT, JNK/MAPK, and p53 pathways while suppressing apoptosis and ferroptosis. The protein further influences the tumor microenvironment by regulating exosome biogenesis, which contributes to intercellular communication and altered sensitivity to agents like temozolomide. Conversely, LRRC8A can transport intracellular cGAMP to activate STING signaling, potentially augmenting antitumor immunity.

In neurology, LRRC8A serves as a critical mediator in the pathogenesis of epilepsy, ischemic stroke, and neurodegenerative diseases. In temporal lobe epilepsy, astrocytic LRRC8A overexpression triggers pathological glutamate release, fostering neuronal hyperexcitability and seizure susceptibility. During ischemic stroke, inhibition of LRRC8A attenuates calpain/caspase-3 activation and reduces infarction volume, indicating its potential as a neuroprotective target.

Emerging evidence further implicates LRRC8A in metabolic and immune regulation. As a nutrient sensor, it regulates adipocyte differentiation and insulin signaling; its disruption contributes to obesity and type 2 diabetes. In the immune system, LRRC8A modulates lymphocyte development and cytokine production.
Therapeutic inhibition of LRRC8A-VRAC holds promising potential in precision oncology (e.g., restoring p53-mediated apoptosis), neuroprotection against stroke/epilepsy, improving metabolic resilience, and augmenting immunotherapy.

In conclusion, LRRC8A represents a multifunctional regulator whose dysregulation contributes to the pathogenesis of cancer, neurological disorders, metabolic diseases, and immune dysfunction, marking it as a high-value target for precision medicine.

Reference

Title of the original paper : LRRC8A A multifaceted regulator in cancer, neurological disorders, metabolic diseases and immune modulation

Journal : Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101773

Funding Information:

• Key Research and Development Projects of Hubei Province, China (No. SCZ202111)
• National Natural Science Foundation of China (No. 82203793)
• Postdoctoral Science Foundation of China (No. 2024M761032)

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 8.4
Impact Factor: 9.4

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #